Literature DB >> 19388970

Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes.

G D Xiang1, J H Pu, L S Zhao, H L Sun, J Hou, L Yue.   

Abstract

AIMS: Osteoprotegerin (OPG) is a recently identified inhibitor of bone resorption. Recent studies indicate that OPG is also associated with endothelial dysfunction in Type 2 diabetes. The aim was to investigate the relationship between plasma OPG levels and urinary albumin excretion (UAE) in Type 2 diabetic patients.
METHODS: This study included 154 newly diagnosed Type 2 diabetic patients and 46 healthy subjects. Plasma OPG and 24-h UAE were measured. High-resolution ultrasound was used to measure flow-mediated (endothelium-dependent arterial) dilation (FMD).
RESULTS: Compared with the normoalbuminuric subgroup, OPG levels in the microalbuminuric subgroup were significantly higher, and OPG levels in macroalbuminuria subgroup were significantly higher than those in the normoalbuminuria and albuminuria subgroups. Multiple regression analysis showed that only FMD (r = -0.26), C-reactive protein (r = 0.23), fasting blood glucose (r = 0.25), 2-h blood glucose (r = 0.21), HbA(1c) (r = 0.28), UAE (r = 0.27) and retinopathy (r = 0.27) were significant factors associated with OPG. Pearson's correlation analyses showed a positive correlation between OPG and logUAE (r = 0.440) and negative correlations between OPG and FMD (r = -0.284), and between FMD and logUAE (r = -0.602).
CONCLUSIONS: Plasma OPG levels are significantly associated with UAE in Type 2 diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19388970     DOI: 10.1111/j.1464-5491.2009.02683.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  4 in total

1.  Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males?

Authors:  P Rozas Moreno; R Reyes García; A García-Martín; M Varsavsky; J A García-Salcedo; M Muñoz-Torres
Journal:  J Endocrinol Invest       Date:  2012-02-28       Impact factor: 4.256

2.  The association of insulin resistance with serum osteoprotegerin in obese adolescents.

Authors:  Joanna Suliburska; Pawel Bogdanski; Ewa Gajewska; Grazyna Kalmus; Magdalena Sobieska; Wlodzimierz Samborski
Journal:  J Physiol Biochem       Date:  2013-05-22       Impact factor: 4.158

3.  Contrast agent suppresses endothelium-dependent arterial dilation after digital subtraction angiography procedure in patients with diabetic foot.

Authors:  Lin Xiang; Guangda Xiang; Junxia Zhang; Ling Yue; Linshuang Zhao
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

4.  Association of osteoprotegerin with impaired glucose regulation and microalbuminuria: the REACTION study.

Authors:  Yixin Niu; Zhen Yang; Xiaoyong Li; Weiwei Zhang; Shuai Lu; Hongmei Zhang; Xueru Chen; Lingfei Zhu; Yin Xing; Guang Ning; Li Qin; Qing Su
Journal:  BMC Endocr Disord       Date:  2015-12-01       Impact factor: 2.763

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.